The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –– Interim ...

The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

With cancer diagnoses and death rates in Michigan often higher than the national average, a new, patient-centered ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers ...

The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...